LMWH versus Warfarin for the Prevention of Recurrent VTE in Patients with Cancer (CLOT Trial)
EBM, Landmark Research
Low-molecular-weight heparin (LMWH) rather than warfarin is routinely recommended for patients with venous thromboembolism (VTE) and active cancer. Much of that is based on this article. Think about these as you review the article: Clinical Question: In patients with cancer…